**6. Conclusions**

The current status of boron neutron capture therapy (BNCT) for brain tumors was reviewed, including recent advances in BNCT, which is still not mature, although its clinical application has begun following the successful launch of an acceleratorbased neutron generation device. The contribution of "boron research" to the further development of BNCT will be important, and many researchers will be involved in the future progress of this field.

Research on the development of boron agents for treatment has also become active, and as introduced here, "multi-targeted BNCT," which simultaneously combines multiple boron agents, is very promising for personalized cancer therapy and the extension of applications.
